Trial Profile

A Phase II, Open-Label, Multicenter Study of Olinvacimab in Combination With Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 05 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olinvacimab (Primary) ; Pembrolizumab (Primary)
Indications Advanced breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms KEYNOTE-C14
Sponsors PharmAbcine

Most Recent Events

30 Dec 2025 Status changed from recruiting to discontinued.
03 Nov 2023 Planned number of patients changed from 36 to 30.
27 Dec 2021 According to a PharmAbcine media release, Professor. Arlene Chan is the principal investigator of this study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com